<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Theor Biol</journal-id><journal-id journal-id-type="iso-abbrev">J. Theor. Biol</journal-id><journal-title-group><journal-title>Journal of Theoretical Biology</journal-title></journal-title-group><issn pub-type="ppub">0022-5193</issn><issn pub-type="epub">1095-8541</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7331570</article-id><article-id pub-id-type="publisher-id">S0022-5193(20)30234-4</article-id><article-id pub-id-type="doi">10.1016/j.jtbi.2020.110379</article-id><article-id pub-id-type="publisher-id">110379</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cost-efficiency analysis of voluntary vaccination against <italic>n</italic>-serovar diseases using antibody-dependent enhancement: A game approach</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Kabir</surname><given-names>K.M. Ariful</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Tanimoto</surname><given-names>Jun</given-names></name><xref rid="af015" ref-type="aff">c</xref><xref rid="af005" ref-type="aff">a</xref></contrib><aff id="af005"><label>a</label>Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga-koen, Kasuga-shi, Fukuoka 816-8580, Japan</aff><aff id="af010"><label>b</label>Department of Mathematics, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh</aff><aff id="af015"><label>c</label>Faculty of Engineering Sciences, Kyushu University, Kasuga-koen, Kasuga-shi, Fukuoka 816-8580, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="pmc-release"><day>2</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>21</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>2</day><month>7</month><year>2020</year></pub-date><volume>503</volume><fpage>110379</fpage><lpage>110379</lpage><history><date date-type="received"><day>6</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>16</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">To investigate a multi-serotype disease alongside antibody-dependent-enhancement; ADE, this article is introducing two kinds of vaccination; primary and secondary vaccines.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">Our framework dovetails mathematical epidemiological model; incorporating SVIRS epidemic model, with evolutionary decision dynamics.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">The primary vaccine targets susceptible people, while the secondary one aims once infected but now recovered individuals letting them avoid &#x02018;second infection&#x02019; which means critical situation.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0020">We quantitatively argue, how effectively the primary and secondary vaccines to minimize such socially critical situation.</p></list-item></list></p></abstract><abstract id="ab010"><p>Records of epidemics acknowledge immunological multi-serotype illnesses as an important aspect of the occurrence and control of contagious diseases. These patterns occur due to antibody-dependent-enhancement (ADE) among serotype diseases, which leads to infection of secondary infectious classes. One example of this is dengue hemorrhagic fever and dengue shock syndrome, which comprises the following four serotypes: DEN-1, DEN-2, DEN-3, and DEN-4. The evolutionary vaccination game approach is able to shed light on this long-standing issue in a bid to evaluate the success of various control programs. Although immunization is regarded as one of the most accepted approaches for minimizing the risk of infection, cost and efficiency are important factors that must also be considered. To analyze the <inline-formula><mml:math id="M1" altimg="si44.svg"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>-serovar aspect alongside ADE consequence in voluntary vaccination, this study establishes a new mathematical epidemiological model that is dovetailed with evolutionary game theory, an approach through which we explored two vaccine programs: primary and secondary. Our findings illuminate that the &#x02018;cost-efficiency&#x02019; effect for vaccination decision exhibits an impact on controlling <inline-formula><mml:math id="M2" altimg="si44.svg"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>-serovar infectious diseases and should be designed in such a manner as to avoid adverse effects. Furthermore, our numerical result justifies the fact that adopting ADE significantly boosted emerging disease incidence, it also suggest that the joint vaccine policy works even better when the complex cyclical epidemic outbreak takes place among multi serotypes interactions. Research also exposes that the primary vaccine is a better controlling tool than the secondary; however, introducing a highly-efficiency secondary vaccine against secondary infection plays a key role to control the disease prevalence.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Vaccination game</kwd><kwd>N-serovar</kwd><kwd>ADE factor</kwd><kwd>Secondary vaccination</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">In the present study, we design on the strengths of existing research and considered the epidemic model and vaccination game and multi-serotype approaches, which in turn is based on evolutionary game theory and gives rise to the human decision-making process. The theoretical approach pioneered by <xref rid="b0005" ref-type="bibr">Kermack and McKendrick (1927)</xref> and others (<xref rid="b0010" ref-type="bibr">Anderson and May, 1979</xref>, <xref rid="b0015" ref-type="bibr">Jones and Sleeman, 1983</xref>, <xref rid="b0020" ref-type="bibr">Goffman and Newill, 1964</xref>) played an important role in epidemiology in terms of the control and prevention of contagious diseases. Recently, this area of study has been accentuated due to the advent of a new strain of pandemic diseases such as influenza, smallpox, SARS (severe acute respiratory syndrome), pneumonia, and dengue fever, among others. Precisely, if we are concerned more to control infectious diseases by immunization, pathogens become more robust to survive and developed new antigenic strains (<xref rid="b0025" ref-type="bibr">Ferguson et al., 1999</xref>, <xref rid="b0030" ref-type="bibr">Vaughn et al., 2000</xref>). One such &#x02018;enhanced disease&#x02019; phenomenon is attributed to antibody-dependent enhancement (ADE), which gives rise to a bolstered viral growth rate in a secondary infection following recovery from a primary infection caused by a variety of serovars (<xref rid="b0035" ref-type="bibr">Recker et al., 2009</xref>, <xref rid="b0040" ref-type="bibr">Billings et al., 2007</xref>, <xref rid="b0045" ref-type="bibr">Billings et al., 2008</xref>) (see <xref rid="f0005" ref-type="fig">Fig. 1</xref>
). Antibody-dependent enhancement represents an evolutionary advancement in multi-strain viruses that makes vaccination difficult. More specifically, this enhancement presents obstacles to optimal immunization that includes all strains of a disease. The reason for this is that newly developed vaccines against only one serotype can increase the possibility of infection by a second serotype. This is particularly risky for people suffering from dengue fever and its related conditions, because infections in this case are particularly severe.<fig id="f0005"><label>Fig. 1</label><caption><p>Schematic phase diagram of Antibody-Depending Enhancement (ADE) effect for four-serovars dengue disease: DEN 1, DEN 2, DEN 3 and DEN 4. The mechanism of ADE may be perceived when an individual who has previously infected (primary infected) with one serotype of the dengue infected again (secondary infected) months or years later with a different serotype. While an individual is infected with one serotype dengue disease (say DEN 1), the immune response developed antibodies against this particular serotype (DEN 1: green) dengue disease that prevents the virus from binding to macrophage cells. However, if another serotype of dengue virus: DEN 2/DEN 3/DEN 4 (orange/red/blue) infect the same individual, the immune system is misled because the four serotypes have similar surface antigens. The antibodies cannot recognize the surface protein of the newly attacked virus which proceeds to infect individual because it has not been inactivated by antibodies. This phenomenon is defined as Antibody-dependent enhancement (ADE) that creates the contagious disease much more terrible. The primary infected form mostly minor disease whereas the secondary infected is more likely to be associated with dengue hemorrhagic fever. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0030">Among multi-serotypes epidemics, dengue fever, one of the most devastating mosquito-borne viral infections to humans, is a significant problem worldwide (<xref rid="b0050" ref-type="bibr">Bhatt et al., 2013</xref>, <xref rid="b0055" ref-type="bibr">Shepard et al., 2016</xref>). The disease is caused by infection with any of four virus serotypes: DEN-1, DEN-2, DEN-3, and DEN-4 (<xref rid="b0060" ref-type="bibr">Ferrar et al., 2014</xref>). The virus affects more than 3.9 billion people in 128 countries in the tropical and subtropical regions of the world, and 52% of people are at risk in Asian and Latin American countries (<xref rid="b0065" ref-type="bibr">Bhatia et al., 2013</xref>, <xref rid="b0070" ref-type="bibr">Messina et al., 2014</xref>, <xref rid="b0075" ref-type="bibr">Brady et al., 2012</xref>). While researchers and drug authorities are currently developing and testing several promising vaccines, one vaccine is currently commercially available for dengue fever (<xref rid="b0080" ref-type="bibr">WHO, 2018</xref>, <xref rid="b0090" ref-type="bibr">Thisyakorn, 2014</xref>). The world&#x02019;s first dengue vaccine was CYD-TDV (brand name Dengvaxia). Created by Sanofi Pasteur (<xref rid="b0080" ref-type="bibr">WHO, 2018</xref>, <xref rid="b0085" ref-type="bibr">FDA, 2019</xref>) it was licensed in 2015 and commercially introduced in selected countries (<xref rid="b0095" ref-type="bibr">Reuters, 2017</xref>, <xref rid="b0100" ref-type="bibr">Susie, 2016</xref>, <xref rid="b0105" ref-type="bibr">Zachri and Planasari, 2016</xref>). Recently, Takeda&#x02019;s vaccine verified protection against virologically confirmed dengue (VCD), and vaccine trials ended (<xref rid="b0110" ref-type="bibr">Biswal et al., 2019</xref>). The current form of all available dengue vaccines (Sanofi Pasteur and Takeda) target individuals previously infected (<xref rid="b0110" ref-type="bibr">Biswal et al., 2019</xref>, <xref rid="b0115" ref-type="bibr">WHO, 2018</xref>), and the vaccine aimed at avoiding second infection. However, for those who have not previously been infected, the vaccine is not as effective. Regarding current vaccination and serotype processes linked to dengue fever, the sequence of infection to which an individual is exposed should be considered. Strategies for self-protection from risk will greatly influence whether first and/or second infections occur. In the case of dengue fever, the most efficient protective measure is vaccination. In this context, the so-called <italic>vaccination game</italic> can be an effective approach for modeling such a complex and dynamic system, where epidemiological dynamics in society can be considered alongside the social evolution of individual decision-making for committing to vaccination in view of governmental policy.</p><p id="p0035">The concept of the vaccination game relies on evolutionary game theory (EGT) alongside an epidemiological compartment model. EGT is a powerful framework for modeling the evolution of cooperation in biological and social sciences. It is the prevailing theoretical framework for understanding social and complex epidemic dynamics (<xref rid="b0120" ref-type="bibr">Smith, 1974</xref>, <xref rid="b0125" ref-type="bibr">Tanimoto, 2015</xref>, <xref rid="b0130" ref-type="bibr">Tanimoto, 2019</xref>). Epidemiology with vaccination as a major issue in the study of evolutionary biology has been widely researched in the past few decades (<xref rid="b0135" ref-type="bibr">Kabir et al., 2019a</xref>, <xref rid="b0140" ref-type="bibr">Kabir and Tanimoto, 2019</xref>, <xref rid="b0145" ref-type="bibr">Wang et al., 2016</xref>, <xref rid="b0150" ref-type="bibr">Bauch and Earn, 2004</xref>, <xref rid="b0155" ref-type="bibr">Kuga et al., 2019</xref>, <xref rid="b0160" ref-type="bibr">Fukuda et al., 2014</xref>, <xref rid="b0165" ref-type="bibr">Fukuda and Tanimoto, 2016</xref>, <xref rid="b0170" ref-type="bibr">Iwamura and Tanimoto, 2018</xref>, <xref rid="b0175" ref-type="bibr">Kabir et al., 2019b</xref>). More recently, a number of precursors used theoretical models to better understand epidemic dynamics in both local (single epidemic season) and global (repeated seasons) time scales, in order to explore how to control contagious diseases. Among them, notable studies include <xref rid="b0180" ref-type="bibr">Kabir and Tanimoto (2019)</xref> for indicating a <italic>meta</italic>-population migration model, <xref rid="b0185" ref-type="bibr">Kuga and Tanimoto (2018)</xref> for the imperfectness of vaccines using both a multi-agent simulation and theoretical approach, <xref rid="b0190" ref-type="bibr">Tanaka and Tanimoto (2020)</xref> for presenting a subsidy model, <xref rid="b0195" ref-type="bibr">Kabir et al., 2020</xref>, <xref rid="b0200" ref-type="bibr">Kabir and Tanimoto, 2019</xref> for the vaccination game approach with heterogeneous network and buzz effect, and Alam et al.&#x02019;s (<xref rid="b0205" ref-type="bibr">Kabir et al., 2019c</xref>) vaccination game model for introducing the secondary effect of a vaccine in repeated seasons. Additionally, <xref rid="b0210" ref-type="bibr">Kabir and Tanimoto (2019)</xref> established a mathematical model of SVIR at a local time scale by allowing for the effectiveness of imperfect vaccination, whereas, <xref rid="b0215" ref-type="bibr">Bauch and Bhattacharyya (2012)</xref> and others (<xref rid="b0220" ref-type="bibr">Chen and Fu, 2018</xref>, <xref rid="b0225" ref-type="bibr">Bauch, 2005</xref>) succeeded in establishing local time evolutionary epidemic models based on the social learning approach. Additionally, <xref rid="b0230" ref-type="bibr">Kabir and Tanimoto (2019)</xref> studied the theoretical epidemic model by combining both vaccination and a treatment game approach to explain the impact of secondary provisions as a fail-safe effect. Recently, <xref rid="b0235" ref-type="bibr">Arefin et al. (2019)</xref> presented the two-strain with two vaccinations game model by tracking repeated seasons.</p><p id="p0040">Based on the literature, within the vaccination game framework, human decision-making and behavior is multi-modally affected by self-interest, vaccination cost, neighbors&#x02019; attitudes, and vaccination risk. All of these factors may play an important role in decreasing the risk for both vaccinated and non-vaccinated (free rider) individuals. However, all of the research noted above involving the vaccination game approach presumed vaccination as pre-emptive and lasting only one season. More importantly, the research adopted vaccines that were primarily aimed at treating influenza-like diseases. In the present study, we created a novel realistic model for the vaccination game approach for dengue-like disease treatment by taking into account ADE, where two vaccinations are introduced within a time sequence. Here, primary vaccination should be applied prior to initial infection, with the secondary vaccine following the first infection. Furthermore, spreading of the disease and updating the treatment strategy should be restructured using the same time scale, and the immunity lasts until it wanes.</p><p id="p0045">The main goal of this work is to provide a benchmark for allowing the study of an epidemiological model for dengue transmission once vaccination has been affected. In doing so, the study focuses on representing the effect of ADE and <italic>n</italic>-serovar aspects within the evolutionary game framework. The two types of vaccinations, primary and secondary, were based on the respective dynamics of vaccination rate among individuals, which is affected by individual perceptions of both infection risk and cost burden. The model further allowed for investigating the relationship between ADE, serotypes, and cost-efficiency and how these might influence a vaccine within an evolutionary framework context.</p><p id="p0050">The paper is ordered as follows. First, we formulate our model in detail. This is followed by introducing an evolutionary mechanism for the strategy-updating rule, i.e., modified replicator dynamics. After describing the model, we present simulation results and discuss their implications. Finally, we conclude the paper with a brief discussion of major findings in the conclusion section.</p></sec><sec id="s0010"><label>2</label><title>Model setup</title><p id="p0055">A modified SVIRS epidemic model in which primary and secondary vaccinations took place is proposed herein to study the influence of primary and secondary infection incidence (due to serotype). Based on the actual ADE mechanism of 4-serovars dengue disease presenting in <xref rid="f0005" ref-type="fig">Fig. 1</xref>, the proposed epidemic model assumed <italic>infection</italic>, <italic>vaccination</italic>, and <italic>recovered</italic> as primary and secondary states. The details of how an individual would ensue for four serotypes is shown in <xref rid="f0010" ref-type="fig">Fig. 2</xref>
(A). The model adopted a two-phase (epidemic and evolutionary) model to include an infinite and diverse population (<xref rid="f0010" ref-type="fig">Fig. 2</xref>(B)). It was presumed that an individual could choose whether to have the primary vaccine administered before primary infection and that the same choice was available for commitment to a secondary vaccination once primary recovery was complete but secondary infection had not yet occurred. Individual decisions arise from the evolution of expected payoff and whether a committing provision (primary or secondary vaccination) is perceived as beneficial. We assumed that a primary recovered state from initial infection with any one serotype provided natural life-long immunity against said serotype but led to the enhancement of other serotypes upon secondary infection. Under these circumstances, the total population was divided into seven states: susceptible<inline-formula><mml:math id="M3" altimg="si45.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, primary vaccinated <inline-formula><mml:math id="M4" altimg="si46.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, primary infected <inline-formula><mml:math id="M5" altimg="si47.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, primary recovered <inline-formula><mml:math id="M6" altimg="si48.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, secondary vaccinated <inline-formula><mml:math id="M7" altimg="si49.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, secondary infected <inline-formula><mml:math id="M8" altimg="si50.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, and secondary recovered <inline-formula><mml:math id="M9" altimg="si51.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The set of dynamic equations presented in this work considered the mean field approximation method alongside a compartmental model. Here, <italic>S</italic> represents susceptible individuals (not yet infected), <inline-formula><mml:math id="M10" altimg="si52.svg"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M11" altimg="si53.svg"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> denotes the fractions of primary infected and primary recovered individuals with <inline-formula><mml:math id="M12" altimg="si54.svg"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> serotypes, respectively, <inline-formula><mml:math id="M13" altimg="si55.svg"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> represents the fraction of secondary infected individuals with <inline-formula><mml:math id="M14" altimg="si56.svg"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> serotypes already recovered from serotype <inline-formula><mml:math id="M15" altimg="si54.svg"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="M16" altimg="si57.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> is the fraction of secondary recovered individuals defined as being in a final recovered state. Meanwhile, <inline-formula><mml:math id="M17" altimg="si58.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M18" altimg="si59.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> are the fractions of primary and secondary vaccinated individuals from a susceptible and primary recovered state, specified by variables <inline-formula><mml:math id="M19" altimg="si3.svg"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M20" altimg="si7.svg"><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:math></inline-formula>, respectively, and defined as the incidental rate of vaccinators. The fraction of individuals in <inline-formula><mml:math id="M21" altimg="si60.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M22" altimg="si57.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> decayed, respectively, since such an immunized state does not continue in perpetuity but returns to the susceptible state at the rate of <inline-formula><mml:math id="M23" altimg="si61.svg"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>. Furthermore, <inline-formula><mml:math id="M24" altimg="si62.svg"><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M25" altimg="si8.svg"><mml:mrow><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> represent infection rate (<inline-formula><mml:math id="M26" altimg="si54.svg"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> serotype), primary recovery rate, and secondary recovery rate, respectively. The efficiency of vaccines is given as <inline-formula><mml:math id="M27" altimg="si63.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M28" altimg="si64.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, referring to the probability of immunity serving to avoid infection, despite receiving both primary and secondary vaccines. Regarding the schematic diagram in <xref rid="f0010" ref-type="fig">Fig. 2</xref>, the SVIRS model was designed as per the system of differential equations given below:<disp-formula id="e0005"><label>(1)</label><mml:math id="M29" altimg="si65.svg"><mml:mrow><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mo linebreak="goodbreak">=</mml:mo><mml:mo linebreak="badbreak">-</mml:mo><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mi>S</mml:mi><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>x</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0010"><label>(2)</label><mml:math id="M30" altimg="si66.svg"><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>x</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="badbreak">-</mml:mo><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0015"><label>(3)</label><mml:math id="M31" altimg="si67.svg"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo linebreak="goodbreak">=</mml:mo><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0020"><label>(4)</label><mml:math id="M32" altimg="si68.svg"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>R</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">-</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo linebreak="badbreak">-</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="italic">yR</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0025"><label>(5)</label><mml:math id="M33" altimg="si69.svg"><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>y</mml:mi><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">-</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0030"><label>(6)</label><mml:math id="M34" altimg="si70.svg"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo linebreak="goodbreak">=</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">+</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0035"><label>(7)</label><mml:math id="M35" altimg="si71.svg"><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>R</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>
<fig id="f0010"><label>Fig. 2</label><caption><p>Schematic image of (A) the transfer chart for S-4 <inline-formula><mml:math id="M36" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> diseases and (B) the entire dynamic model. Relevant parameters are: (i) the probability that susceptible individuals will become infected, <inline-formula><mml:math id="M37" altimg="si2.svg"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>; (ii) the probability that susceptible people will receive primary vaccination, <inline-formula><mml:math id="M38" altimg="si3.svg"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula>; (iii) the probability that a primary infected individual will recover, <inline-formula><mml:math id="M39" altimg="si4.svg"><mml:mrow><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>; (iv) the probability that a primary recovered individual will again be infected, <inline-formula><mml:math id="M40" altimg="si5.svg"><mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, due to the effect of ADE factor <inline-formula><mml:math id="M41" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>; (iv) the probability that primary recovered people will be vaccinated, <inline-formula><mml:math id="M42" altimg="si7.svg"><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:math></inline-formula>; (v) the probability that secondary infected people will recover, <inline-formula><mml:math id="M43" altimg="si8.svg"><mml:mrow><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>; (vi) the probability that vaccinated individuals will be infected due to the imperfectness of a vaccine <inline-formula><mml:math id="M44" altimg="si9.svg"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> in the case of primary and <inline-formula><mml:math id="M45" altimg="si10.svg"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> secondary vaccinations.</p></caption><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0060">Referring to selected precursors (<xref rid="b0035" ref-type="bibr">Recker et al., 2009</xref>, <xref rid="b0040" ref-type="bibr">Billings et al., 2007</xref>, <xref rid="b0045" ref-type="bibr">Billings et al., 2008</xref>) as a guideline, we introduce force of infection for <inline-formula><mml:math id="M46" altimg="si44.svg"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> serotypes, <inline-formula><mml:math id="M47" altimg="si72.svg"><mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>&#x022ef;</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, defined as the ADE factor, where <inline-formula><mml:math id="M48" altimg="si73.svg"><mml:mrow><mml:msub><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ji</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>&#x0003e;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is given by:<disp-formula id="e0040"><label>(8)</label><mml:math id="M49" altimg="si74.svg"><mml:mrow><mml:msub><mml:mi>&#x003c8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ji</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ji</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p id="p0065">As a general assumption, we analyzed the symmetric case defined by the setting of various contact rates and ADE factors of all serotypes, equal to: <inline-formula><mml:math id="M50" altimg="si75.svg"><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M51" altimg="si76.svg"><mml:mrow><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M52" altimg="si77.svg"><mml:mrow><mml:msub><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ji</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>. A total <inline-formula><mml:math id="M53" altimg="si44.svg"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> primary and <inline-formula><mml:math id="M54" altimg="si78.svg"><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>n</mml:mi><mml:mo linebreak="badbreak">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> secondary infection groups existed; the possible number of infections an individual could contract was up to <inline-formula><mml:math id="M55" altimg="si44.svg"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> times. Here, we analyzed two cases for <inline-formula><mml:math id="M56" altimg="si79.svg"><mml:mrow><mml:mi>n</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> defined as 2-serovar (hereafter, S-2) and <inline-formula><mml:math id="M57" altimg="si80.svg"><mml:mrow><mml:mi>n</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>4</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> defined as 4-serovar (S-4) disease.</p></sec><sec id="s0015"><label>3</label><title>Dual decision-making processes</title><p id="p0070">To explore the evolutionary trail arising from human decision-making processes related to vaccination uptake as a rational choice, we considered a modified replicator dynamic by referring to existing studies (<xref rid="b0210" ref-type="bibr">Kabir and Tanimoto, 2019</xref>, <xref rid="b0215" ref-type="bibr">Bauch and Bhattacharyya, 2012</xref>). In this context, individuals attempted to change their strategies using a probability proportional to the expected gain or loss of payoff. For the current context, in the evolutionary process, people incorporated two types of decision-making processes: primary and secondary vaccination. Here, an individual can become vaccinated against being susceptible to primary infection and receive secondary vaccination following primary recovery. The payoff in both instances depends on the difference between (a) the penalty of risking infection and (b) the drawbacks of being vaccinated. The drawback of the vaccine for primary and secondary vaccination can be quantified as <inline-formula><mml:math id="M58" altimg="si81.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M59" altimg="si82.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>, and the penalty of being infected due to primary and secondary infection can be evaluated as <inline-formula><mml:math id="M60" altimg="si83.svg"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M61" altimg="si84.svg"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula>. This was derived from the premise that the relative expected cost of primary (secondary) vaccination was <inline-formula><mml:math id="M62" altimg="si85.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="M63" altimg="si86.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the vaccination cost and <inline-formula><mml:math id="M64" altimg="si87.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is infection cost (here, <inline-formula><mml:math id="M65" altimg="si88.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. Consequently, the expression <inline-formula><mml:math id="M66" altimg="si89.svg"><mml:mrow><mml:mo linebreak="badbreak" linebreakstyle="after">-</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo linebreak="badbreak" linebreakstyle="after">+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M67" altimg="si90.svg"><mml:mrow><mml:mo linebreak="badbreak" linebreakstyle="after">-</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo linebreak="badbreak" linebreakstyle="after">+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> quantifies the expected payoff gain for changing strategies and its sign controls whether the vaccination or non-vaccination option is preferred. The global dynamics of <inline-formula><mml:math id="M68" altimg="si3.svg"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M69" altimg="si7.svg"><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:math></inline-formula> can be depicted as follows:<disp-formula id="e0045"><label>(9)</label><mml:math id="M70" altimg="si91.svg"><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>m</mml:mi><mml:mi>x</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo linebreak="badbreak">+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="e0050"><label>(10)</label><mml:math id="M71" altimg="si92.svg"><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>m</mml:mi><mml:mi>y</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">-</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mo linebreak="badbreak">-</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mo linebreak="badbreak">+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M72" altimg="si93.svg"><mml:mrow><mml:mi>x</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> is the rate observed at time <inline-formula><mml:math id="M73" altimg="si94.svg"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula> at which susceptible individuals become primarily vaccinated, and <inline-formula><mml:math id="M74" altimg="si95.svg"><mml:mrow><mml:mi>y</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> is the rate at which primary (temporal) recovered individuals become secondarily vaccinated. Furthermore, <inline-formula><mml:math id="M75" altimg="si96.svg"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:math></inline-formula> is the proportionality constant that alter the fraction of population into the transferring rate; throughout this study, we assumed<inline-formula><mml:math id="M76" altimg="si97.svg"><mml:mrow><mml:mi>m</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math></inline-formula>.</p><p id="p0075">The numerical simulation will be carried out for the stated equations (1&#x02013;10) of the epidemic model by using the explicit finite difference method. Initially, we presumed the initial conditions for all simulations as, <inline-formula><mml:math id="M77" altimg="si98.svg"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>S</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M78" altimg="si99.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.00001</mml:mn></mml:mrow></mml:math></inline-formula>. We also assumed that the initial incidental rate of vaccinators to be <inline-formula><mml:math id="M79" altimg="si100.svg"><mml:mrow><mml:mi>x</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.00001</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M80" altimg="si101.svg"><mml:mrow><mml:mi>y</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.00001</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p></sec><sec id="s0020"><label>4</label><title>Results and discussion</title><p id="p0080">In this study, we investigated the diffusion of multi-serotype diseases based on the SVIRS epidemic model and the evolutionary game approach, where two vaccines were disseminated within a population. The stability of the model was reviewed by plotting timeline graphs based on the endemic equilibrium shown in <xref rid="f0015" ref-type="fig">Fig. 3</xref>
for the S-2 (solid line) and S-4 (dotted line) diseases. Panels A, B, C, D, E, F, and G, respectively, represent the portion of individuals for the following: susceptible, primary infection <inline-formula><mml:math id="M81" altimg="si102.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, secondary infection <inline-formula><mml:math id="M82" altimg="si103.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, primary vaccination (<inline-formula><mml:math id="M83" altimg="si58.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>), secondary vaccination (<inline-formula><mml:math id="M84" altimg="si59.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>), primary recovered <inline-formula><mml:math id="M85" altimg="si104.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and secondary recovered (<inline-formula><mml:math id="M86" altimg="si57.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>). Moreover, we considered two combination of efficiency-cost cases <inline-formula><mml:math id="M87" altimg="si105.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#x003b7;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as follows: <inline-formula><mml:math id="M88" altimg="si106.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for a less efficient and costly vaccine (blue) and <inline-formula><mml:math id="M89" altimg="si107.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for a highly efficient and cheaper vaccine (red), where <inline-formula><mml:math id="M90" altimg="si14.svg"><mml:mrow><mml:mi>&#x003b7;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M91" altimg="si15.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. For comparison, we included a case without vaccination (black). The numerical simulations were conducted using the following model parameter values: <inline-formula><mml:math id="M92" altimg="si30.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M93" altimg="si42.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="M94" altimg="si16.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M95" altimg="si108.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> Throughout the numerical results provided below, we fixed <inline-formula><mml:math id="M96" altimg="si109.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M97" altimg="si110.svg"><mml:mrow><mml:mi>&#x003b1;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.008</mml:mn></mml:mrow></mml:math></inline-formula>.<fig id="f0015"><label>Fig. 3</label><caption><p>Dynamic behavior of a system comprising S-2 and S-4 diseases with <inline-formula><mml:math id="M98" altimg="si11.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2.0</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.008</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula>and <inline-formula><mml:math id="M99" altimg="si12.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#x003b7;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (blue), <inline-formula><mml:math id="M100" altimg="si13.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#x003b7;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (red), and without vaccination (gray). Time series of (A) susceptible, (B) primary infection, (C) secondary infection, (D) primary vaccination, (E) secondary vaccination, (F) primary recovered, and (G) secondary recovered. Here, <inline-formula><mml:math id="M101" altimg="si14.svg"><mml:mrow><mml:mi>&#x003b7;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M102" altimg="si15.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M103" altimg="si16.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M104" altimg="si17.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="M105" altimg="si18.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr3_lrg"/></fig></p><p id="p0085">Comparing S-2 with S-4 diseases, we observed an increase in serotype diversity causing a subsequent rise in disease incidence (panels B and C). A similar tendency was also observed in the case of both vaccinated and secondary recovered individuals (panels D, E, and G). Enhancement of serotype diversity increased the portion of both vaccinated and secondary recovered groups. However, only one exception was observed for the primary recovered (panel F) group, suggesting that an increase in serotype diminished the portion of recovered individuals. This can be fully justified by the fact that a higher number of disease serotypes intensified the transmission from primary recovered to secondary infection. Additionally, <xref rid="f0015" ref-type="fig">Fig. 3</xref> highlights that the impact of both vaccinations (primary and secondary) suppressed the spread of the disease when compared with non-vaccination or the default settings (no vaccination and evolutionary mechanism taking place). Furthermore, it appears that a higher efficiency at a cheaper cost delivered higher vaccination uptake, which in turn reduced infection for both primary and secondary incidences. The opposite tendency was observed in the case of less efficient and more expensive vaccines. According to results in general, even though more individuals will benefit from either primary or secondary vaccination, an epidemic cannot be eradicated by these two vaccination types as employed in the parameter settings noted here.</p><p id="p0090">The discussion above nonetheless indicates that the model was successful, indicating an appropriate dynamic that is to some degree able to achieve a state of equilibrium. Thus, in the following discussion, we focus on the results observed at equilibrium for a variety of model parameters.</p><p id="p0095">In order to derive an insightful understanding of how ADE factors and disease transmission function for two different serotypes (S-2 and S-4), we present a two-dimensional (2D) heat map of primary infected, secondary infected, primary vaccinated, and secondary vaccinated groups in <xref rid="f0020" ref-type="fig">Figs. 4</xref>
(a), (b) and <xref rid="f0025" ref-type="fig">5</xref>
(a), (b), respectively. In each figure, panel A and panel B display the S-2 and S-4 disease for two vaccine efficiencies <inline-formula><mml:math id="M106" altimg="si111.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> as (*-i) <inline-formula><mml:math id="M107" altimg="si112.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M108" altimg="si113.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula>, (*-iii) <inline-formula><mml:math id="M109" altimg="si114.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-iv) <inline-formula><mml:math id="M110" altimg="si115.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> and for their corresponding costs <inline-formula><mml:math id="M111" altimg="si116.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula> as (a-*) <inline-formula><mml:math id="M112" altimg="si117.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula>, (b-*), <inline-formula><mml:math id="M113" altimg="si118.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math></inline-formula>, (c-*) <inline-formula><mml:math id="M114" altimg="si119.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (d-*) <inline-formula><mml:math id="M115" altimg="si120.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:math></inline-formula>. Each sub-panel provides a 2D phase plane for the ADE factor, i.e., <inline-formula><mml:math id="M116" altimg="si121.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02264;</mml:mo><mml:mi>&#x003c6;</mml:mi><mml:mo>&#x02264;</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> and for infection rate, i.e., <inline-formula><mml:math id="M117" altimg="si122.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>&#x02264;</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>&#x02264;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Throughout, we can see from <xref rid="f0020" ref-type="fig">Fig. 4</xref> that the fraction of infected individuals increased as ADE factor <inline-formula><mml:math id="M118" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula> increased. Since ADE factor defined quantifying enhancement of synergetic contact in the secondary infection rate, it was expected to play a significant role in increasing disease outbreaks. Meanwhile, it was observed that the outcome exhibited two equilibrium points, a disease-free state <inline-formula><mml:math id="M119" altimg="si123.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and an endemic state <inline-formula><mml:math id="M120" altimg="si124.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x0003e;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="M121" altimg="si125.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> was the basic reproduction number defined as <inline-formula><mml:math id="M122" altimg="si126.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>&#x003c3;</mml:mi></mml:mrow></mml:math></inline-formula> and, as already noted, we fixed <inline-formula><mml:math id="M123" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>. Accordingly, the disease will regress if <inline-formula><mml:math id="M124" altimg="si127.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.1</mml:mn><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>,</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:math></inline-formula> presented by the deep blue region of <xref rid="f0020" ref-type="fig">Fig. 4</xref>, that also brings no vaccination area (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). Another aspect that may also affect the fraction of both primary and secondary infected individuals is relevant vaccines cost <inline-formula><mml:math id="M125" altimg="si128.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and their efficiency being <inline-formula><mml:math id="M126" altimg="si129.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. From this result, three primary factors were observed, as discussed below.<fig id="f0020"><label>Fig. 4</label><caption><p>(a): Phase diagrams of primary infection individuals along infection rate <inline-formula><mml:math id="M127" altimg="si19.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula> and ADE factor <inline-formula><mml:math id="M128" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost <inline-formula><mml:math id="M129" altimg="si20.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (a-*) <inline-formula><mml:math id="M130" altimg="si21.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (b-*) <inline-formula><mml:math id="M131" altimg="si22.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (c-*) <inline-formula><mml:math id="M132" altimg="si23.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (d-*) <inline-formula><mml:math id="M133" altimg="si24.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and the outcome of variable efficiency <inline-formula><mml:math id="M134" altimg="si25.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (*-i) <inline-formula><mml:math id="M135" altimg="si26.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M136" altimg="si27.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-iii) <inline-formula><mml:math id="M137" altimg="si28.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-v) <inline-formula><mml:math id="M138" altimg="si29.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Additional parameters are <inline-formula><mml:math id="M139" altimg="si30.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M140" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>. (b): Phase diagrams of secondary infection individuals along infection rate <inline-formula><mml:math id="M141" altimg="si19.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula> and ADE factor <inline-formula><mml:math id="M142" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost <inline-formula><mml:math id="M143" altimg="si20.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (a-*) <inline-formula><mml:math id="M144" altimg="si21.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (b-*) <inline-formula><mml:math id="M145" altimg="si22.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (c-*) <inline-formula><mml:math id="M146" altimg="si23.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (d-*) <inline-formula><mml:math id="M147" altimg="si32.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, and the outcome of varying efficiency <inline-formula><mml:math id="M148" altimg="si25.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (*-i) <inline-formula><mml:math id="M149" altimg="si26.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M150" altimg="si27.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-iii) <inline-formula><mml:math id="M151" altimg="si28.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-v) <inline-formula><mml:math id="M152" altimg="si29.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The remaining parameters are <inline-formula><mml:math id="M153" altimg="si30.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M154" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>.</p></caption><graphic xlink:href="gr4a_lrg"/><graphic xlink:href="gr4b_lrg"/></fig><fig id="f0025"><label>Fig. 5</label><caption><p>(a): Phase diagrams for primary vaccination individuals along infection rate <inline-formula><mml:math id="M155" altimg="si19.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula> and ADE factor <inline-formula><mml:math id="M156" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost <inline-formula><mml:math id="M157" altimg="si20.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (a-*) <inline-formula><mml:math id="M158" altimg="si21.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (b-*) <inline-formula><mml:math id="M159" altimg="si22.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (c-*) <inline-formula><mml:math id="M160" altimg="si23.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (d-*) <inline-formula><mml:math id="M161" altimg="si24.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and the outcome of varying efficiency <inline-formula><mml:math id="M162" altimg="si25.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (*-i) <inline-formula><mml:math id="M163" altimg="si26.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M164" altimg="si27.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-iii) <inline-formula><mml:math id="M165" altimg="si28.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-v) <inline-formula><mml:math id="M166" altimg="si29.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The remaining parameters are <inline-formula><mml:math id="M167" altimg="si30.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M168" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>. (b): Phase diagrams of secondary vaccination individuals along infection rate <inline-formula><mml:math id="M169" altimg="si19.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula> and ADE factor <inline-formula><mml:math id="M170" altimg="si6.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow></mml:math></inline-formula>. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost <inline-formula><mml:math id="M171" altimg="si20.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (a-*) <inline-formula><mml:math id="M172" altimg="si21.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (b-*) <inline-formula><mml:math id="M173" altimg="si22.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (c-*) <inline-formula><mml:math id="M174" altimg="si23.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (d-*) <inline-formula><mml:math id="M175" altimg="si24.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and the outcome of varying efficiency <inline-formula><mml:math id="M176" altimg="si25.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> as (*-i) <inline-formula><mml:math id="M177" altimg="si26.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M178" altimg="si27.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, (*-iii) <inline-formula><mml:math id="M179" altimg="si28.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-v) <inline-formula><mml:math id="M180" altimg="si29.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The remaining parameters are <inline-formula><mml:math id="M181" altimg="si30.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M182" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>.</p></caption><graphic xlink:href="gr5a_lrg"/><graphic xlink:href="gr5b_lrg"/></fig></p><p id="p0100">First, the higher efficiency and lower cost for primary vaccination (sub-panels (a-iii), (a-iv), (b-iii), and (b-iv)) encouraged people to receive primary vaccination (<xref rid="f0025" ref-type="fig">Fig. 5</xref>(a)), which naturally led to a lower rate of primary infection (<xref rid="f0020" ref-type="fig">Fig. 4</xref>(a)).</p><p id="p0105">Second, for one of the four combinations above (sub-panel (a-iv)), higher efficiency and lower cost were implemented not only for the first but also secondary vaccinations, the results indicating a lower rate of secondary vaccination (<xref rid="f0025" ref-type="fig">Fig. 5</xref>(b) (a-iv)). Therefore, we can state that this particular tendency is not uncommon but likely, since there were fewer people who were infected in the secondary infection group (<xref rid="f0020" ref-type="fig">Fig. 4</xref>(b) (a-iv)). These results indicate that primary vaccination worked effectively and so many people taking the primary immunization policy. As a result, there was no need to receive secondary vaccination.</p><p id="p0110">Third, and similar to the first point, the higher efficiency and lower cost of the secondary vaccination (sub-panels (a-ii), (c-ii), and (c-iv)) encouraged people to commit to receiving secondary vaccination (<xref rid="f0025" ref-type="fig">Fig. 5</xref>(b)), which reduced the size of secondary infection (<xref rid="f0020" ref-type="fig">Fig. 4</xref>(b)). Although the case of (a-iv) should be one of above those, it does not indicate a high fraction of secondary vaccination. The reason why this happens was what we already discussed in the previous paragraph.</p><p id="p0115">Visually comparing the S-2 and S-4 cases (as per comparison of panel A and panel B in <xref rid="f0020" ref-type="fig">Fig. 4</xref>, <xref rid="f0025" ref-type="fig">Fig. 5</xref>), shows the outcome likewise, where S-4 cases demonstrated relatively higher infectious situations but a smaller vaccinated region.</p><p id="p0120">To establish appropriate provisions within society for exploring effective financial support policy (e.g., subsidy, discounts, or free-tickets) to control the spread of disease, we present another 2D heat map in <xref rid="f0030" ref-type="fig">Fig. 6</xref>
. The figure indicates secondarily infected (S-4) individuals (<inline-formula><mml:math id="M183" altimg="si130.svg"><mml:mrow><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula>) along with primary vaccine efficiency <inline-formula><mml:math id="M184" altimg="si33.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and secondary vaccine efficiency <inline-formula><mml:math id="M185" altimg="si34.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. In the case of dengue fever, a portion of secondary infected individuals will be exposed to danger of death; research is needed to effectively reduce this number. Here, sub-panels (a-*), (b-*), and (c-*) indicate preferences for primary vaccination <inline-formula><mml:math id="M186" altimg="si35.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, the default setting <inline-formula><mml:math id="M187" altimg="si36.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, and a preference for secondary vaccination <inline-formula><mml:math id="M188" altimg="si131.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. As a reference, sub-panel (d-*) indicates preference for both vaccinations <inline-formula><mml:math id="M189" altimg="si38.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Here, we used the term &#x02018;preference&#x02019; to imply the specific vaccination that the public health authority prioritized. For example, &#x02018;preference of primary vaccination&#x02019; implies that governmental subsidy for encouraging primary vaccination (cheaper cost; <italic>C<sub>p</sub></italic> can be derived vis-a-vis the default case) exists. Additionally, sub-panels (*-i), (*-ii), and (*-iii) present the variation of infection rates for <inline-formula><mml:math id="M190" altimg="si39.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="M191" altimg="si132.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="M192" altimg="si133.svg"><mml:mrow><mml:mn>0.4</mml:mn></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="M193" altimg="si134.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>), and 0.8 (<inline-formula><mml:math id="M194" altimg="si135.svg"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math></inline-formula>).<fig id="f0030"><label>Fig. 6</label><caption><p>Phase diagram for secondary infection individuals with S-4 along primary efficiency <inline-formula><mml:math id="M195" altimg="si33.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and secondary efficiency <inline-formula><mml:math id="M196" altimg="si34.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. The preference for primary vaccination as <inline-formula><mml:math id="M197" altimg="si35.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, default case as <inline-formula><mml:math id="M198" altimg="si36.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, preference for secondary vaccination as <inline-formula><mml:math id="M199" altimg="si37.svg"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and preference for both vaccinations as <inline-formula><mml:math id="M200" altimg="si38.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> are presented in sub-panels (a-*), (b-*), (c-*), and (d-*), respectively. Here, the infection rate is varied as (*-i) <inline-formula><mml:math id="M201" altimg="si39.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M202" altimg="si40.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-iii) <inline-formula><mml:math id="M203" altimg="si41.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>. The remaining parameters are <inline-formula><mml:math id="M204" altimg="si42.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M205" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>.</p></caption><graphic xlink:href="gr6_lrg"/></fig></p><p id="p0125">Deliberately observing all panels, we observed that the width of the blue region (from light to deep blue) shown in the Y-axis (extending in the <inline-formula><mml:math id="M206" altimg="si33.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>-direction) was wider than in the X-axis (extending in the <inline-formula><mml:math id="M207" altimg="si34.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>-direction); however, the extent of the blue color in the X-axis region was darker than in the Y-axis. This tendency was more evidently observed in the dotted box of panel (d&#x02013;i) (presuming weaker infection rate and a preference for both vaccination types). This tendency can also be observed in other parameter settings.</p><p id="p0130">The above observation implies the following. To suppress secondary infection, secondary vaccination requires high efficiency (reliability). However, if a higher <inline-formula><mml:math id="M208" altimg="si34.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> can be realized, the effect will become significant. Contrastingly, the primary vaccination, despite not having higher efficiency for <inline-formula><mml:math id="M209" altimg="si33.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> will still work reasonably effective in terms of suppressing secondary infection. This can be attributed to the secondary vaccination being introduced at a more downstream point within the process of infection dynamics, as shown in <xref rid="f0010" ref-type="fig">Fig. 2</xref>, compared to where primary vaccination is situated. Thus, a much more drastic effect is needed to subdue the spread of secondary infection. However, once this has been established, the impact of secondary vaccination will be significant.</p><p id="p0135">The next step is to provide analogous phase diagrams for secondary infected (*-i), susceptible (*-ii), primary vaccinated (*-iii), and secondary vaccinated (*-iv) individuals against a S-4 according to variable infection rates (a-*) <inline-formula><mml:math id="M210" altimg="si39.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>, (b-*) <inline-formula><mml:math id="M211" altimg="si40.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (c-*) <inline-formula><mml:math id="M212" altimg="si41.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula> (see <xref rid="f0035" ref-type="fig">Fig. 7</xref>
). In doing so, the assumption of a low-cost vaccine is made for both costs <inline-formula><mml:math id="M213" altimg="si136.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> introduced above, in a case where both vaccinations are equally emphasized by the public health authority. It is worth noting that the dotted triangles for the weaker infection rate (<inline-formula><mml:math id="M214" altimg="si39.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>) display higher susceptibility but lower secondary infection, despite relatively lower coverage for both vaccinations. Referring to existing studies (<xref rid="b0125" ref-type="bibr">Tanimoto, 2015</xref>, <xref rid="b0130" ref-type="bibr">Tanimoto, 2019</xref>, <xref rid="b0135" ref-type="bibr">Kabir et al., 2019a</xref>), this indicates that &#x02018;free-riding&#x02019; on the so-called &#x02018;herd immunity&#x02019; does occur, as a high efficiency for both vaccinations and relatively weaker infection rate only requires limited vaccination coverage within a society in order to stop the disease from spreading. This allows for a reasonable percentage of free-riders (no vaccination) to be present in the society.<fig id="f0035"><label>Fig. 7</label><caption><p>Full phase diagrams of (*-i) secondary infection (*-ii), susceptible (*-iii), primary vaccination, and (*-iv) secondary vaccination individuals for S-4 disease along primary efficiency <inline-formula><mml:math id="M215" altimg="si33.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and secondary efficiency <inline-formula><mml:math id="M216" altimg="si34.svg"><mml:mrow><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. Here, the infection rate is varied as (*-i) <inline-formula><mml:math id="M217" altimg="si39.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></inline-formula>, (*-ii) <inline-formula><mml:math id="M218" altimg="si40.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and (*-iii) <inline-formula><mml:math id="M219" altimg="si41.svg"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>. The remaining parameters are <inline-formula><mml:math id="M220" altimg="si31.svg"><mml:mrow><mml:mi>&#x003c3;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M221" altimg="si43.svg"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M222" altimg="si42.svg"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula>.</p></caption><graphic xlink:href="gr7_lrg"/></fig></p></sec><sec id="s0025"><label>5</label><title>Conclusion</title><p id="p0140">Applying the vaccination game approach to epidemics, we proposed an <italic>n</italic>-serovar SVIRS disease model for studying the effect of ADE for two vaccination types, primary and secondary, as it relates to the control and preclusion of contagious diseases. Model investigations and numerical simulations were carried out by including two voluntary vaccination options with several parameters including vaccination cost, efficiency, and ADE factor for two serotypes (S-2 and S-4). Our model can easily be extended to a generalized <italic>n</italic>-serotype model for arbitrary infections. The model presumed modified replicator dynamics and a mean field approximation, i.e., an infinite and diverse population.</p><p id="p0145">We found an established vaccination policy implemented by health authorities for controlling vaccination efficiency (investment required for improving vaccination efficiency) and the cost to individuals for being vaccinated (subsidies allowing for vaccination) to be crucial to infectious systems in which dual vaccinations are implemented. Additionally, the ADE effect also enhanced contagious disease where infections were involved.</p><p id="p0150">We posited that secondary vaccination should be addressed if its efficiency can be established as being high. Secondary vaccination works at an immediately antecedent stage in the sequence of an infectious process; therefore, irrespective of how effective primary vaccination is, a highly efficient secondary vaccine will be able to minimize death casualties by, among others, dengue fever.</p><p id="p0155">Contrastingly, if a highly efficient secondary vaccination is less conceivable, primary vaccination must take on the burden of stopping the disease from spreading. This implies that an appropriate combination of primary and secondary vaccinations will need to be designed.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0160">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Kermack</surname><given-names>W.O.</given-names></name><name><surname>McKendrick</surname><given-names>A.G.</given-names></name></person-group><article-title>A Contribution to the mathematical theory of epidemics</article-title><source>Proc. Roy. Soc. Lond. A</source><volume>115</volume><year>1927</year><fpage>700</fpage><lpage>721</lpage></element-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.M.</given-names></name><name><surname>May</surname><given-names>R.M.</given-names></name></person-group><article-title>Population biology of infectious diseases: Part I</article-title><source>Nature</source><volume>280</volume><year>1979</year><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">460412</pub-id></element-citation></ref><ref id="b0015"><mixed-citation publication-type="other" id="h0015">Jones, D.S., Sleeman, B.D., 1983. Differential Equations and Mathematical Biology. London, Allen &#x00026; Unwin.</mixed-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Goffman</surname><given-names>W.</given-names></name><name><surname>Newill</surname><given-names>V.A.</given-names></name></person-group><article-title>Generalization of epidemic theory: an application to the transmission of ideas</article-title><source>Nature</source><volume>204</volume><year>1964</year><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">14212412</pub-id></element-citation></ref><ref id="b0025"><mixed-citation publication-type="other" id="h0025">Ferguson, N., Anderson, R., Gupta, S., 1999. The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Poc. Natl. Acad. Sci. USA 96, 790&#x02013;794.</mixed-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>D.W.</given-names></name></person-group><article-title>Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity</article-title><source>J. Infect. Dis.</source><volume>181</volume><year>2000</year><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10608744</pub-id></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Recker</surname><given-names>M.</given-names></name><name><surname>Blyuss</surname><given-names>K.B.</given-names></name><name><surname>Simmons</surname><given-names>C.P.</given-names></name><name><surname>Hien</surname><given-names>T.T.</given-names></name><name><surname>Wills</surname><given-names>B.</given-names></name><name><surname>Farrar</surname><given-names>J.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Immunological serotype interactions and their effect on the epidemiological pattern of dengue</article-title><source>Proc. R. Soc. B</source><volume>276</volume><year>2009</year><fpage>2541</fpage><lpage>2548</lpage></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Billings</surname><given-names>L.</given-names></name><name><surname>Schwartz</surname><given-names>I.B.</given-names></name><name><surname>Shaw</surname><given-names>L.B.</given-names></name><name><surname>McCrary</surname><given-names>M.</given-names></name><name><surname>Burke</surname><given-names>D.S.</given-names></name><name><surname>Cummings</surname><given-names>D.A.T.</given-names></name></person-group><article-title>Instabilities in multiserotype disease models with antibody-dependent enhancement</article-title><source>J. Theor. Biol.</source><volume>246</volume><year>2007</year><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">17270219</pub-id></element-citation></ref><ref id="b0045"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Billings</surname><given-names>L.</given-names></name><name><surname>Fiorillo</surname><given-names>A.</given-names></name><name><surname>Schwartz</surname><given-names>I.B.</given-names></name></person-group><article-title>Vaccinations in disease models with antibody-dependent enhancement</article-title><source>Math. Biol.</source><volume>211</volume><year>2008</year><fpage>265</fpage><lpage>281</lpage></element-citation></ref><ref id="b0050"><mixed-citation publication-type="other" id="h0050">Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., et al., 2013. The global distribution and burden of dengue. Nature 496, 504&#x02013;507.</mixed-citation></ref><ref id="b0055"><mixed-citation publication-type="other" id="h0055">Shepard, D.S., Undurraga, E.A., Halasa, Y.A., Stanaway, J.D., 2016. The global economic burden of dengue&#x02019; a systematic analysis. Lancet Infect. Dis. 16, 935&#x02013;941.</mixed-citation></ref><ref id="b0060"><mixed-citation publication-type="other" id="h0060">Ferrar, J., Hotez, P.J., Junghanss, T., Kang, G., Lalloo, D., White, N.J., et al., 2014. Monson&#x02019;s Tropical Infectious Diseases, Elsevier.</mixed-citation></ref><ref id="b0065"><mixed-citation publication-type="other" id="h0065">Bhatia, R., Dash, A., Sunyoto, T., 2013. Changing epidemiology of dengue in South-East Asia. WHO-SEAJPH 2, 23&#x02013;27.</mixed-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Messina</surname><given-names>J.P.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Scott</surname><given-names>T.W.</given-names></name></person-group><article-title>Global spread of dengue virus types: mapping the 70 years history</article-title><source>Trends Microbiol.</source><volume>22</volume><year>2014</year><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">24468533</pub-id></element-citation></ref><ref id="b0075"><mixed-citation publication-type="other" id="h0075">Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen, A.G., et al., 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl. Trop. Dis. 6 (8), e1760.</mixed-citation></ref><ref id="b0080"><mixed-citation publication-type="other" id="h0080">Dengue vaccine: WHO position paper &#x02013; September 2018, 2018. Weekly Epidemiol. Record 93 (36), 457&#x02013;76.</mixed-citation></ref><ref id="b0085"><mixed-citation publication-type="other" id="h0085">Dengvaxia, U.S. Food and Drug Administration (FDA), 2019. STN 125682.</mixed-citation></ref><ref id="b0090"><mixed-citation publication-type="other" id="h0090">Thisyakorn, U., 2014. Latest developments and future directions in dengue vaccines. Therapeut. Adv. Vaccines 2 (1), 3&#x02013;9.</mixed-citation></ref><ref id="b0095"><mixed-citation publication-type="other" id="h0095">Sanofi's dengue vaccine approved in 11 countries. Reuters. 2017.</mixed-citation></ref><ref id="b0100"><mixed-citation publication-type="other" id="h0100">Susie, E., 2016. World's first dengue fever vaccine launched in the Philippines, CNN</mixed-citation></ref><ref id="b0105"><mixed-citation publication-type="other" id="h0105">Zachri, E., Planasari, S., 2016. Dengue Fever Vaccine Available in Indonesia, WIB, October 17, 2016</mixed-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Biswal</surname><given-names>B.M.D.</given-names></name></person-group><article-title>Efficacy of a tetravalent dengue vaccine in healthy children and adolescents</article-title><source>N. Engl. J. Med.</source><volume>381</volume><year>2019</year><fpage>2009</fpage><pub-id pub-id-type="pmid">31693803</pub-id></element-citation></ref><ref id="b0115"><mixed-citation publication-type="other" id="h0115">World Health Organization; Dengue vaccine: WHO position paper &#x02013; September 2018. Weekly Epidemiol. Record 93 (36), 457&#x02013;76 (September 2018).</mixed-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.M.</given-names></name></person-group><article-title>Theory of games and evolution of animal conflicts</article-title><source>J. Theor. Biol.</source><volume>47</volume><year>1974</year><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">4459582</pub-id></element-citation></ref><ref id="b0125"><mixed-citation publication-type="other" id="h0125">Tanimoto, J., 2015. Fundamental of Evolutionary Game Theory and its Applications, Springer.</mixed-citation></ref><ref id="b0130"><mixed-citation publication-type="other" id="h0130">Tanimoto, J., 2019. Evolutionary Games with Sociophysics: Analysis of Traffic Flow and Epidemics, Springer.</mixed-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Kuga</surname><given-names>K.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Analysis of SIR epidemic model with information spreading of awareness</article-title><source>Cha. Sol. Frac.</source><volume>119</volume><year>2019</year><fpage>118</fpage><lpage>125</lpage></element-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Analysis of epidemic outbreaks in two-layer networks with different structures for information spreading and disease diffusion</article-title><source>Commun. Nonlinear Sci. Numer. Simul.</source><volume>72</volume><year>2019</year><fpage>565</fpage><lpage>574</lpage></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Bauch</surname><given-names>C.T.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>d'Onofrio</surname><given-names>A.</given-names></name><name><surname>Manfredi</surname><given-names>P.</given-names></name><name><surname>Perc</surname><given-names>M.</given-names></name><name><surname>Perra</surname><given-names>N.</given-names></name><name><surname>Salath&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name></person-group><article-title>Statistical physics of vaccination</article-title><source>Phys. Rep.</source><volume>664</volume><year>2016</year><fpage>1</fpage><lpage>113</lpage></element-citation></ref><ref id="b0150"><mixed-citation publication-type="other" id="h0150">Bauch, C.T., Earn, D.J., 2004. Vaccination and the theory of games. Proc. Natl. Acad. Sci. USA 101, 13391&#x02013;13394.</mixed-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Kuga</surname><given-names>K.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name><name><surname>Jusup</surname><given-names>M.</given-names></name></person-group><article-title>To vaccinate or not to vaccinate: a comprehensive study of vaccination-subsidizing policies with multi-agent simulations and mean-field modeling</article-title><source>J. Theor. Biol.</source><volume>469</volume><year>2019</year><fpage>107</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">30807759</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>E.</given-names></name><name><surname>Kokubo</surname><given-names>S.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Hagishima</surname><given-names>A.</given-names></name><name><surname>Ikegaya</surname><given-names>N.</given-names></name></person-group><article-title>Risk assessment for infectious disease and its impact on voluntary vaccination behavior in social network</article-title><source>Cha. Sol. Frac.</source><volume>68</volume><year>2014</year><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>E.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Effects of stubborn decision-makers on vaccination and disease propagation in social network</article-title><source>Int. J. Autom. Logist.</source><volume>2</volume><year>2016</year><fpage>78</fpage><lpage>92</lpage></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Iwamura</surname><given-names>Yoshiro</given-names></name><name><surname>Tanimoto</surname><given-names>Jun</given-names></name></person-group><article-title>Realistic decision-making processes in a vaccination game</article-title><source>Phys. A Stat. Mech. Appl.</source><volume>494</volume><year>2018</year><fpage>236</fpage><lpage>241</lpage></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Kuga</surname><given-names>K.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Effect of information spreading to suppress the disease contagion on the epidemic vaccination game</article-title><source>Cha. Sol. Frac.</source><volume>119</volume><year>2019</year><fpage>180</fpage><lpage>187</lpage></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Evolutionary vaccination game approach in metapopulation migration model with information spreading on different graphs</article-title><source>Cha. Sol. Frac.</source><volume>120</volume><year>2019</year><fpage>41</fpage><lpage>55</lpage></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Kuga</surname><given-names>K.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Which is more effective for suppressing an infectious disease: imperfect vaccination or defense against contagion?</article-title><source>JSTATE Theory Exp.</source><volume>2</volume><year>2018</year><object-id pub-id-type="publisher-id">023407</object-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Is subsidizing vaccination with hub agent priority policy really meaningful to suppress disease spreading?</article-title><source>J. Theor. Biol.</source><volume>486</volume><year>2020</year><object-id pub-id-type="publisher-id">110059</object-id></element-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Kuga</surname><given-names>K.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>The impact of information spreading on epidemic vaccination game dynamics in a heterogeneous complex network-a theoretical approach</article-title><source>Cha. Sol. Frac.</source><volume>132</volume><year>2020</year></element-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Vaccination strategies in a two-layer SIR/V&#x02013;UA epidemic model with costly information and buzz effect</article-title><source>Commun. Nonlinear Sci. Numer. Simul.</source><volume>76</volume><year>2019</year><fpage>92</fpage><lpage>108</lpage></element-citation></ref><ref id="b0205"><mixed-citation publication-type="other" id="h0205">Kabir, K.M.A., Jusup, M., Tanimoto, J., 2019. Behavioral incentives in a vaccination-dilemma setting with optional treatment, PRE 100, 062402.</mixed-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Dynamical behaviors for vaccination can suppress infectious disease &#x02013; a game theoretical approach</article-title><source>Cha. Sol. Frac.</source><volume>123</volume><year>2019</year><fpage>229</fpage><lpage>239</lpage></element-citation></ref><ref id="b0215"><mixed-citation publication-type="other" id="h0215">Bauch, C.T., Bhattacharyya, S., 2012. Evolutionary game theory and social learning can determine how vaccine scares unfold. PLoS Comp. Biol. 8 (4), e1002452.</mixed-citation></ref><ref id="b0220"><mixed-citation publication-type="other" id="h0220">Chen, X., Fu, F., 2018. Social learning of prescribing behavior can promote population optimum of antibiotic use, Front. Phys. 6, 139.</mixed-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Bauch</surname><given-names>T.C.</given-names></name></person-group><article-title>Imitation dynamics predict vaccinating behavior</article-title><source>Proc. R. Soc. B</source><volume>272</volume><year>2005</year><fpage>1669</fpage><lpage>1675</lpage></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>K.M.A.</given-names></name><name><surname>Tanimoto</surname><given-names>J.</given-names></name></person-group><article-title>Modeling and analyzing the coexistence of dual dilemmas in the proactive vaccination game and retroactive treatment game in epidemic viral dynamics</article-title><source>Proc. R. Soc. A</source><volume>475</volume><year>2019</year><fpage>20190484</fpage><pub-id pub-id-type="pmid">31892836</pub-id></element-citation></ref><ref id="b0235"><mixed-citation publication-type="other" id="h0235">Arefin, M.R., Masaki, T., Kabir, K.M.A., Tanimoto, J., 2019. Interplay between cost and effectiveness in influenza vaccine uptake: a vaccination game approach. Proc. R. Soc. A 475, 20190608.</mixed-citation></ref></ref-list><ack id="ak005"><sec id="s0030"><title>Acknowledgments</title><p id="p0165">This study was partially supported by Grant-in-Aid for Scientific Research from <funding-source id="gp015"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001691</institution-id><institution>JSPS</institution></institution-wrap></funding-source>, Japan, KAKENHI (Grant No. JP19KK0262), <funding-source id="gp010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100006091</institution-id><institution>SCAT</institution></institution-wrap></funding-source> (Support Center for Advanced Telecommunications Technology) <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005930</institution-id><institution>Research Foundation</institution></institution-wrap></funding-source>, and I/O Data Foundation awarded to Professor Tanimoto. We would like to express our gratitude to them.</p></sec><sec sec-type="data-availability" id="s0035"><title>Data availability</title><p id="p0170">The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec id="s0040"><title>Author statement</title><p id="p0175">Kabir K M Ariful conceived of the presented idea and established the theory and performed the computations. Jun Tanimoto encouraged Ariful Kabir to explore and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.</p></sec></ack></back></article>